<- Go Home
Mirna Therapeutics, Inc.
As of August 28, 2017, Mirna Therapeutics, Inc was acquired by Synlogic, Inc in a reverse merger transaction. Mirna Therapeutics, Inc. does not have significant operations. It intends to identify and evaluate strategic alternatives, including a merger or sale of the company. Previously, the company was engaged in the development of microRNA-based oncology therapeutics. The company was founded in 2007 and is headquartered in Austin, Texas.
Market Cap
$38.1M
Volume
11.3K
Cash and Equivalents
$15.2M
EBITDA
-$20.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$18.34
52 Week Low
$7.84
Dividend
N/A
Price / Book Value
0.82
Price / Earnings
-1.34
Price / Tangible Book Value
0.82
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$20.4M
Return on Equity
47.28%
Return on Assets
-20.33
Cash and Short Term Investments
$47.7M
Debt
N/A
Equity
$46.7M
Revenue
N/A
Unlevered FCF
-$13.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium